| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0167-7799(96)10062-7 |
| P698 | PubMed publication ID | 9032990 |
| P2093 | author name string | Morrison SL | |
| Wright A | |||
| P2860 | cites work | Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution | Q27729251 |
| Assembly of asparagine-linked oligosaccharides | Q28131690 | ||
| In vitro antibodies: strategies for production and application | Q33215595 | ||
| The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region | Q36361038 | ||
| Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. | Q36363690 | ||
| Recognition sites on human IgG for Fc gamma receptors: the role of glycosylation | Q38300484 | ||
| A protein structural change in aglycosylated IgG3 correlates with loss of huFc gamma R1 and huFc gamma R111 binding and/or activation | Q38338507 | ||
| Proton nuclear magnetic resonance studies of the structure of the Fc fragment of human immunoglobulin G1: comparisons of native and recombinant proteins | Q38340695 | ||
| Antibody-dependent cytotoxicity mediated by natural killer cells is enhanced by castanospermine-induced alterations of IgG glycosylation | Q38342853 | ||
| Localization of the binding site for the human high-affinity Fc receptor on IgG. | Q38347512 | ||
| Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor | Q38352603 | ||
| The Structure and Biology of Human IgD | Q39712594 | ||
| Glycosylation mutants of animal cells | Q40118939 | ||
| Clinical issues in antibody design. | Q40475415 | ||
| Immunotherapeutic potential of antibodies produced in plants | Q40965916 | ||
| Biochemical analysis of the N-glycosylation pathway in baculovirus-infected lepidopteran insect cells. | Q41290328 | ||
| Control of IgG/Fc glycosylation: a comparison of oligosaccharides from chimeric human/mouse and mouse subclass immunoglobulin Gs. | Q41548700 | ||
| Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody | Q41898883 | ||
| A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins | Q42162369 | ||
| Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors | Q42835972 | ||
| N-glycosylation and in vitro enzymatic activity of human recombinant tissue plasminogen activator expressed in Chinese hamster ovary cells and a murine cell line | Q43473380 | ||
| Fc receptors | Q44298973 | ||
| Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG | Q59067758 | ||
| Protein glycosylation in yeast | Q68178947 | ||
| Interaction of aglycosyl immunoglobulins with the IgG Fc transport receptor from neonatal rat gut: comparison of deglycosylation by tunicamycin treatment and genetic engineering | Q68217209 | ||
| Structural study of the carbohydrate moieties of two human immunoglobulin subclasses (IgG2 and IgG4) | Q69322824 | ||
| The carbohydrate contents of fragments and polypeptide chains of human gamma-G-myeloma proteins of different heavy-chain subclasses | Q70090558 | ||
| The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H | Q71108219 | ||
| Glycosylation of the variable region of immunoglobulin G--site specific maturation of the sugar chains | Q71523039 | ||
| Localization of the carbohydrate within the variable region of light and heavy chains of human gamma g myeloma proteins | Q71540840 | ||
| Structural studies of oligosaccharides of rat IgE and reexamination of the high-mannose oligosaccharide of human IgE | Q71677562 | ||
| Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein | Q71803052 | ||
| Exploring transgenic plants as a new vaccine source | Q72196259 | ||
| Comparative biochemical characterization of a human IgM produced in both ascites and in vitro cell culture | Q72270120 | ||
| Culture pH affects expression rates and glycosylation of recombinant mouse placental lactogen proteins by Chinese hamster ovary (CHO) cells | Q72270530 | ||
| Structural characterization of the N-glycans of a humanized anti-CD18 murine immunoglobulin G | Q72668837 | ||
| Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics? | Q72689325 | ||
| The three-dimensional structure of the carbohydrate within the Fc fragment of immunoglobulin G | Q93857589 | ||
| P433 | issue | 1 | |
| P921 | main subject | antibody | Q79460 |
| glycosylation | Q898365 | ||
| P304 | page(s) | 26-32 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | Trends in Biotechnology | Q2451465 |
| P1476 | title | Effect of glycosylation on antibody function: implications for genetic engineering | |
| P478 | volume | 15 |
| Q36094806 | A human anti-Pseudomonas aeruginosa serotype O6ad immunoglobulin G1 expressed in transgenic tobacco is capable of recruiting immune system effector function in vitro |
| Q77683899 | A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes |
| Q73911228 | A systematic approach to the validation of process control parameters for monoclonal antibody production in fed-batch culture of a murine myeloma |
| Q28079016 | Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life |
| Q33438523 | An HPLC-MALDI MS method for N-glycan analyses using smaller size samples: application to monitor glycan modulation by medium conditions |
| Q30277986 | Analysis of Monoclonal Antibody Sequence and Post-translational Modifications by Time-controlled Proteolysis and Tandem Mass Spectrometry |
| Q47406183 | Animal Cell Expression Systems |
| Q37634941 | Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model |
| Q35026023 | Antibody manufacture in transgenic animals and comparisons with other systems |
| Q60957644 | Biosynthetic Oligoclonal Antivenom (BOA) for Snakebite and Next-Generation Treatments for Snakebite Victims |
| Q51172126 | Capillary electrophoresis analysis of N-glycosylation changes of serum paraproteins in multiple myeloma. |
| Q47598608 | Cell culture media supplementation of infrequently used sugars for the targeted shifting of protein glycosylation profiles |
| Q30344134 | Characterizing biological products and assessing comparability following manufacturing changes. |
| Q45966460 | Choice of cellular protein expression system. |
| Q56656130 | Complement and cellular cytotoxicity in antibody therapy of cancer |
| Q26860800 | Complement in monoclonal antibody therapy of cancer |
| Q30782648 | Comprehensive assessment of N-glycans derived from a murine monoclonal antibody: a case for multimethodological approach |
| Q42645388 | Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa |
| Q38703253 | Different fermentation processes produced variants of an anti-CD52 monoclonal antibody that have divergent in vitro and in vivo characteristics |
| Q35214746 | Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies |
| Q30328190 | Effect of glycosylation on structure and dynamics of MHC class I glycoprotein: a molecular dynamics study. |
| Q51747164 | Effect of lithium chloride on the production and sialylation of Fc-fusion protein in Chinese hamster ovary cell culture. |
| Q30941602 | Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24. |
| Q40353652 | Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc. |
| Q57253528 | Endoglycosidase treatment abrogates IgG arthritogenicity: Importance of IgG glycosylation in arthritis |
| Q31214737 | Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity |
| Q33661333 | Engineering host cell lines to reduce terminal sialylation of secreted antibodies |
| Q38912287 | Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment |
| Q38329171 | Enhancement of sialylation on humanized IgG-like bispecific antibody by overexpression of α2,6-sialyltransferase derived from Chinese hamster ovary cells. |
| Q33309958 | Exchanging murine and human immunoglobulin constant chains affects the kinetics and thermodynamics of antigen binding and chimeric antibody autoreactivity |
| Q30663233 | Expression of single-chain Fv-Fc fusions in Pichia pastoris |
| Q35003386 | Fab fragment glycosylated IgG may play a central role in placental immune evasion |
| Q39217862 | Fcγ Receptor Heterogeneity in Leukocyte Functional Responses. |
| Q33884974 | Foreign protein production in plant tissue cultures |
| Q30728002 | Function and glycosylation of plant-derived antiviral monoclonal antibody |
| Q30872736 | Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments |
| Q34503954 | Galactose-extended glycans of antibodies produced by transgenic plants |
| Q34584868 | Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor |
| Q40942617 | Glycan structure and serum half-life of recombinant CTLA4Ig, an immunosuppressive agent, expressed in suspension-cultured rice cells with coexpression of human β1,4-galactosyltransferase and human CTLA4Ig. |
| Q39298073 | Glycoengineering of CHO Cells to Improve Product Quality |
| Q50880121 | Glycosylation Analysis of Therapeutic Glycoproteins Produced in CHO Cells. |
| Q91657650 | Glycosylation Heterogeneity of Hyperglycosylated Recombinant Human Interferon-β (rhIFN-β) |
| Q45078841 | Heterogeneous conditions in dissolved oxygen affect N-glycosylation but not productivity of a monoclonal antibody in hybridoma cultures. |
| Q39439938 | Human recombinant anti-thyroperoxidase autoantibodies: in vitro cytotoxic activity on papillary thyroid cancer expressing TPO |
| Q55031960 | Identification of human glycosyltransferase genes expressed in erythroid cells predicts potential carbohydrate blood group loci. |
| Q43716326 | Immunochemical localisation of cathepsin S, cathepsin L and MHC class II-associated p41 isoform of invariant chain in human lymph node tissue |
| Q36131665 | Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors |
| Q46091062 | Improving mass accuracy of high performance liquid chromatography/electrospray ionization time-of-flight mass spectrometry of intact antibodies |
| Q28208361 | Improving the efficacy of antibody-based cancer therapies |
| Q28344259 | Influence of growth conditions and developmental stage on N-glycan heterogeneity of transgenic immunoglobulin G and endogenous proteins in tobacco leaves |
| Q33784553 | Inhibition of tumor growth by plant-derived mAb. |
| Q37496563 | Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity |
| Q27473455 | L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus |
| Q30835165 | Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity |
| Q36540601 | Ligand-targeted delivery of therapeutic siRNA. |
| Q40853167 | Low glucose depletes glycan precursors, reduces site occupancy and galactosylation of a monoclonal antibody in CHO cell culture. |
| Q33850508 | Lumazine synthase protein cage nanoparticles as antigen delivery nanoplatforms for dendritic cell-based vaccine development |
| Q37290930 | Mammalian glycosylation in immunity |
| Q48715652 | Metabolic engineering II. Eukaryotic systems |
| Q90227080 | Methamphetamine Impairs IgG1-Mediated Phagocytosis and Killing of Cryptococcus neoformans by J774.16 Macrophage- and NR-9640 Microglia-Like Cells |
| Q37919888 | Modulating antibody pharmacokinetics using hydrophilic polymers |
| Q57341107 | Molecular Modeling for Protein Aggregation and Formulation |
| Q39451572 | Molecular and functional analysis of monoclonal antibodies in support of biologics development |
| Q44279970 | Molecular cloning and chimerisation of an inhibitory anti-cathepsin B antibody and its expression in Chinese hamster ovary cells |
| Q51744834 | Monensin, a small molecule ionophore, can be used to increase high mannose levels on monoclonal antibodies generated by Chinese hamster ovary production cell-lines. |
| Q40814398 | Monitoring impurities in biopharmaceuticals produced by recombinant technology |
| Q51099640 | Monoclonal C5-1 antibody produced in transgenic alfalfa plants exhibits a N-glycosylation that is homogenous and suitable for glyco-engineering into human-compatible structures. |
| Q37677278 | Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles |
| Q38659790 | N-glycoprotein macroheterogeneity: biological implications and proteomic characterization. |
| Q38322902 | N-glycosylation influences epitope expression and receptor binding structures in human IgE. |
| Q34574834 | Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies |
| Q35075181 | Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteins |
| Q89422301 | Overview of Antibody Drug Delivery |
| Q48092860 | Physicochemical Characterization, Glycosylation Pattern and Biosimilarity Assessment of the Fusion Protein Etanercept |
| Q36128912 | Plant biopharming of monoclonal antibodies |
| Q33266823 | Plant-derived mouse IgG monoclonal antibody fused to KDEL endoplasmic reticulum-retention signal is N-glycosylated homogeneously throughout the plant with mostly high-mannose-type N-glycans |
| Q46608396 | Profiling N-linked oligosaccharides from IgG by high-performance anion-exchange chromatography with pulsed amperometric detection |
| Q98466487 | Protein Glycoengineering: An Approach for Improving Protein Properties |
| Q37114428 | Quantitation of Site-Specific Glycosylation in Manufactured Recombinant Monoclonal Antibody Drugs. |
| Q34508329 | Recombinant immunoglobulin A: powerful tools for fundamental and applied research |
| Q44362265 | Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems |
| Q33960542 | Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo |
| Q33276349 | Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys |
| Q26824272 | Structural and functional characteristics of bovine milk protein glycosylation |
| Q34612619 | T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody |
| Q37206320 | The Association Between Glycosylation of Immunoglobulin G and Hypertension: A Multiple Ethnic Cross-Sectional Study |
| Q51748629 | The bioactivity and fractionation of peptide hydrolysates in cultures of CHO cells. |
| Q55353878 | The complement system contributes to functional antibody-mediated responses induced by immunization with Plasmodium falciparum malaria sporozoites. |
| Q36850723 | The constant region contributes to the antigenic specificity and renal pathogenicity of murine anti-DNA antibodies |
| Q52537205 | The effect on immunoglobulin glycosylation of altering in vivo production of immunoglobulin G. |
| Q47984567 | The role of glycosylation in autoimmune disease |
| Q40408971 | The therapeutic potential of plant-derived vaccines and antibodies |
| Q34620112 | The use of high pressure for separation and production of bioactive molecules |
| Q41643628 | Tobacco seeds as efficient production platform for a biologically active anti-HBsAg monoclonal antibody |
| Q30418309 | Top-down mass spectrometry for the analysis of combinatorial post-translational modifications |
| Q34114603 | Transgenic animal bioreactors |
| Q38055447 | With or without sugar? (A)glycosylation of therapeutic antibodies |
Search more.